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Pathology Data in the Centra l Databases of Mult icenter
Randomized Tria ls Need to Be Based on Pathology Reports
and Control led by Trained Qual i ty Managers
By I.D. Nagtegaal, E. Klein Kranenbarg, J. Hermans, C.J.H. van de Velde, J.H.J.M. van Krieken,
and the Pathology Review Committee
Purpose: Randomized multicenter trials form the ba-
sis of health care development. Regarding cancer re-
search, pathology data are crucial. To maintain the
quality of these trials, the auditing of subsequent pro-
cesses is necessary. The aim of the present study was to
examine the completeness and accuracy of data ob-
tained from a special-purpose standardized pathology
form compared with the data available through tradi-
tional hospital pathology reports.
Patients and Methods: A retrospective comparison
of pathology data case record forms with hospital
pathology reports was performed using the data from
300 patients with primary rectal cancer. All of these
patients had been included in a large multicenter trial in
the Netherlands. Three independent audits were car-
ried out. Special attention was given to the accuracy of
parameters, which are important for prognosis and
treatment decisions. Furthermore, various factors that
possibly influence the occurrence of errors were inves-
tigated.
Results: Quality control of the pathology data re-
vealed a high accuracy of 86.5% of all data items.
However, only one third of the forms were complete and
correct. Missing values were most prominent in the num-
ber of lymph nodes examined, whereas most errors were
made in relation to the circumferential margin. Trained
review pathologists made fewer major errors. Discrepan-
cies were detected in all control rounds.
Conclusion: Successive rounds of quality control are
required for accuracy and completeness of pathology
data in multicenter trials. In addition to the special-
purpose pathology forms, original pathology reports
have to be collected, and the data should also be
controlled by a trained pathology quality manager.
J Clin Oncol 18:1771-1779. © 2000 by American
Society of Clinical Oncology.
RANDOMIZED TRIALS are the most important instru-ment in the assessment of the value of treatment.
Because many studies require large numbers of patients,
trials are often multicenter with central data collection.
These data have to be accurate and trustworthy to obtain a
reliable assessment of trial results. In a time when the
outcomes and effectiveness of health care services are main
issues, quality assessment is a particular concern. In both
clinical and experimental medicine, auditing has found its
place. The clinical audit primarily concerns optimal diag-
nosis and patient care, whereas the audit of trials involves
other factors.
Although users of medical record systems assume that the
information in the records is complete and accurate, recent
literature claims the opposite. In the last decade, many
medical data systems have been audited to investigate their
reliability. Although, in general, these databases have a high
rate of completeness (in the range of 95% to 99%),1,2 the
accuracy of their data varies from 70% to 96%.2-7 However,
for some of these databases, accuracy is based on the entry
of data regarding the involved organ and the presence or
absence of pathology alone.7 None of these databases is
concerned with trial research.
In the Netherlands, an ongoing large multicenter trial for
the treatment of rectal cancer is being conducted. This
randomized trial with 83 participating hospitals compares
total mesorectal excision (TME) surgery and preoperative
radiotherapy with TME surgery alone.8 To ensure reliable
outcomes in this trial, radiotherapy, as well as surgery and
pathology, are standardized and under constant quality
control.
Pathologic parameters, such as the tumor-node-metasta-
sis (TNM) classification and, in rectal cancer, the involve-
ment of the circumferential margin, are significant factors
that predict the prognosis of patients. TNM stage, therefore,
is an important item in the evaluation of the effects of
treatment. In the analysis of the prognostic value of these
parameters, high-quality data are vital. For a high-quality
database, the following are required: first, the pathologic
examination procedures should be standardized, and sec-
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ond, the source of the pathology data should be determined.
In general, data managers in clinical trials use special-
purpose pathology forms instead of original pathology
reports to acquire their data. If there is a significant
inaccuracy in the data recorded on the trial pathology case
record form (CRF), the reliability of trials that use only
these forms should be questioned.
In this study, we investigated the reliability of pathology
data on a CRF in a large multicenter clinical trial for rectal
cancer. Therefore, we compared the pathology CRF to the
traditional gold standard (the hospital pathology report). We
conclude that it is necessary to collect a copy of the
pathology report and to have control rounds performed by a
peer review committee and by a specially trained pathology
quality manager, in addition to the standard controlling




The TME trial is a prospective randomized multicenter trial with
standardized surgery and pathology that studies TME surgery with or
without preoperative radiotherapy in the treatment of primary rectal
cancer. Local recurrence is the main outcome measure of the trial. The
TME database is composed of six distinct entry modules: patient
characteristics, radiotherapy, surgery, pathology, follow-up, and qual-
ity of life. This report focuses on pathology data. To ensure a
high-quality database, a pathology peer review committee (PRC) was
used; the main purpose of the peer review was the verification of the
interpretation and the integrity of the pathology data. The PRC
consisted of 12 Dutch pathologists who had a special interest in
gastrointestinal disease.
Study Population
The current report comprises the retrospective analysis of the
accuracy of the pathology data of 300 patients. Patients were selected
whose pathology forms had already been reviewed by a member of the
PRC.
Pathology Requirements
The trial protocol required a standard pathology examination of the
rectal resection specimen according to the guidelines provided by
Quirke et al.9 This included investigation of tumor invasion of the
bowel wall and surrounding tissue, differentiation grade, lymph node
involvement, and resection margin involvement. Before the start of the
trial, protocols, procedures, and forms were explained to the patholo-
gists during a workshop. All participants also received written manuals
and additional information in regular newsletters. They were instructed
to send the CRF together with the hospital pathology report to the
central data office. The traditionally dictated pathology notes were
required by the trial protocol to contain histologic type of tumor, tumor
size and margins, and the amount of examined/positive lymph nodes
and their position. Together with the CRF and the pathology report, the
slide(s) that included the circumferential margin were sent in for
review.
CRF
For data collection, a special-purpose pathology CRF was designed
that consisted of three main fields: tumor margins and size, TNM
classification, and lymph nodes (number and location). These three
fields were divided into 14 entry fields in which both categorical and
quantitative entries occur (Fig 1). The form was completed by the local
hospital pathologist and sent to the central data management office.
The first control of the CRFs was performed by the central data
manager when the forms were received at the trial bureau. After data
input, both the original pathology report and the CRF were sent
together with one hematoxylin and eosin slide to a member of the PRC.
Finally, the pathology quality manager performed a last control.
We did not analyze errors in the M classification, because proven
distant metastasis was an exclusion criterion of the trial. Furthermore,
in the majority of cases, only the rectal resection specimen was
provided. The presence and involvement of the paraaortic lymph nodes
were not analyzed because they were never resected.
Definitions
The reliability of the database was assessed in terms of the accuracy
of the pathology CRFs in reflecting the original hospital pathology
reports from which they were coded. Errors were divided into three
basic categories:
1. Major errors with potential clinical significance. In this category,
we included the errors regarding the extent of disease (TNM
classification and lymph node description) and the completeness
of local excision (circumferential margin involvement).
2. Clerical errors. This category included errors that could be
detected and corrected by careful reexamination of the CRFs: for
example, transposition of the measurements that represented the
distance of the tumor from the proximal and distal margins,
respectively.
3. Minor errors. This category encompassed errors that must be
avoided if a high-quality database is to be maintained but that
were unrelated to pathologic end points of the trial: for example,
errors in the measurement of tumor size.
Data Processing
Individual steps in the process of data reporting were tracked to
determine whether specific variables in the reporting process increased
the error rate. For example, the time lapse between dictation of the
pathology report and the entry of data onto the CRF was analyzed to
determine its impact on error rates. Similarly, it was determined
whether errors made on the CRF differed in frequency depending on
whether the primary pathologist or a colleague performed the data
entry. To examine the effect of training, the error incidence of
pathologists from the PRC were separately investigated. Errors were
not linked to individual pathologists, because the goal of quality
assurance is to produce the best possible database and not to document
pathologists’ errors.
Data Entry and Statistics
For data entry, the Medical Research Data Management database
was used (MRDM 7.0; Project Manager, R. Brand; Leiden, the
Netherlands). Statistical analysis was performed using the Statistical
Product and Service Solutions software (SPSS 7.5 for Windows, SPSS,
Inc, Chicago, IL).
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Fig 1. Pathology collection form consisting of 14 entry fields. The entry fields of M classification and paraaortic lymph node presence and involvement were
not analyzed. Abbreviations: RT, radiotherapy; LN, lymph nodes.
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RESULTS
CRF
The 300 pathology reports were issued from 36 pathology
laboratories. The number of reports from each laboratory
varied from one to 45 (mean, 15.4). Of the 300 CRFs, 98
were complete and consistent with the pathology report
(32.7%); missing values were present in 144 CRFs (48.0%)
and could not be solved in 124 CRFs because of incom-
pleteness of the pathology report. Data items that could not
be retrieved were the number of examined and positive
apical lymph nodes (15.3%), the exact margins (circumfer-
ential, 4.7%; proximal, 8.7%; distal, 5.0%), and tumor sizes
(length 0.3%, width 10.7%). Inconsistencies were also
present in these CRFs. In 58 CRFs, no missing values were
present, but there were inconsistencies with the pathology
report.
General Accuracy
Of 4,170 possible data entries, 341 items were missing on
the original CRF (8.2%), and after correction and comple-
tion, still more than one half of them could not be solved,
which left 195 items missing (4.7%). Of 3,829 scored items,
221 were corrected (5.8%).
Accuracy per Item
Table 1 shows the percentages of missing values and
errors by individual data item. The percentage of missing
values varied from 0.7% (primary tumor) to 21.3% (number
of positive apical lymph nodes). Error rates varied from
0.0% (involvement of proximal and distal margins) to
17.8% (smallest circumferential margin). It can be observed
that accuracy varied considerably for the different data
items, regardless of their importance. Involvement of the
circumferential margin was the main indicator for prognosis
and adjuvant therapy but had a relatively high missing rate
(8.0% [margin involvement]) and error rate (17.8% [small-
est distance to the margin]). On the other hand, proximal
and distal margins, which have no such consequence,
showed much lower missing and error rates (4.7% [margin
involvement] and 9.4% [smallest distance to the margin],
respectively).
TNM Classification
Classification of the tumor according to the TNM guide-
lines was generally well reported. In two cases, however,
both the T and N classifications were missing (0.7%), and in
five other cases, the N classification was missing (1.6%).
Tables 2 and 3 show the changes in both T and N
classifications resulting from completion and correction and
the subsequent stage migration. Correction of the T classi-
fication resulted in downgrading in five cases (1.7%) and
upgrading in nine cases (3.0%) (Table 2). The N classifi-
cation showed underreporting in 10 cases (3.3%) and
overreporting in one case (0.3%). When the N classification
was missing, one could not conclude that all lymph nodes
were negative: only one of the eight missing N classifica-
tions could be replaced by an N0 classification (Table 3).
These corrections resulted in nine subsequent TNM stage
Table 1. Percentage of Missing Values and Errors by Individual Data Item
Data Item No. Missing Values % 95% CI (%) Scored Errors % 95% CI
TNM classification
Primary tumor (T) 300 2 0.7 0.1-2.4 298 14 4.7 2.6-7.8
Regional lymph nodes (N) 300 7 2.3 0.9-4.7 293 14 4.8 2.6-7.9
Lymph nodes
Examined perirectal LN 300 15 5.0 2.8-8.3 285 28 9.8 6.6-3.9
Positive perirectal LN 300 17 5.7 3.3-8.9 283 21 7.4 4.7-11.1
Examined apical LN 300 60 20.0 15.6-25.0 240 10 4.2 2.0-7.5
Positive apical LN 300 64 21.3 16.7-26.0 236 8 3.4 1.5-6.6
Tumor margins and size
Circumferential margin (inv) 300 24 8.0 5.2-11.7 276 17 6.2 3.6-9.7
Circumferential margin (cm) 273* 32 11.7 7.9-15.5 241 43 17.8 13.0-22.7
Proximal margin (inv) 300 14 4.7 2.6-7.7 286 0 0 0-1.3
Proximal margin (cm) 300 33 11.0 7.7-15.1 267 25 9.4 6.2-13.5
Distal margin (inv) 300 11 3.7 1.8-6.5 289 0 0 0-1.3
Distal margin (cm) 297* 25 8.4 5.5-12.2 272 29 10.7 7.0-14.3
Tumor length 300 3 1.0 0.2-2.9 297 6 2.0 0.8-4.3
Tumor width 300 34 11.3 8.0-15.5 266 6 2.3 0.8-4.8
Abbreviations: CI, confidence interval; LN, lymph node; inv, margin involvement (yes/no); cm, smallest distance to the margin (in cm).
*If the margin was positive, no distance was required.
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migrations (3.0%), in four cases to a lower stage (1.4%) and
in five to a higher stage (1.7%) (Fig 2).
Regarding the missing rate of the N classification (2.3%),
the number of examined and positive lymph nodes was
poorly reported, with a general missing rate of 13% (5% to
21%). The error rates of these two items were comparable
(4.8% v 6.4%), which is expected because there is a clear
relationship between them. Investigation of this relationship
revealed that eight cases of errors in N classification were
dependent on errors in the number of lymph nodes present
on the CRF. In two cases, both parameters were incorrect,
but these mistakes were not related. In 11 cases, the number
of examined and positive lymph nodes was correctly noted
but the N classification was incorrect.
In 60 CRFs, the number of examined and positive nodes
was incorrect or incomplete. If we relied on these data for N
classification, correction of these entries would not result in
any different N classification in 48.3%. In 25%, it was not
possible to determine the N classification from the original
information on the CRF, whereas in 26.7%, correction
resulted in a different N classification.
Clerical and Minor Errors
Regarding clerical errors, all errors in the proximal
margin (n 5 25) resulted from the transposition of the
measurements of the distal and proximal margins (9.4%).
Minor errors are listed in Table 1.
Data Processing
Investigation of factors, which could be of any influence,
revealed that there was no relationship between the error
rate and the time lapse between the dictation of the
pathology report and the completion of the CRF. Further-
more, there was no significant difference in error rate
between primary pathologists and their local TME pathol-
ogists in completing the CRF. Pathologists from the PRC
had better performances regarding major errors than did
their non-PRC colleagues (mean major error, 0.86 v 1.48;
Mann-Whitney test: P 5 .001), which shows that experi-
ence in auditing CRFs is important in reducing error rates.
Error Detection
In general, most errors were detected in the first round of
control, which was performed by the data manager (Fig 3).
However, the majority of errors (75%) in the T classification
were detected by the review pathologist or the pathology
quality manager. Also, the determination of errors in the
involvement of the circumferential margin was more than
50% dependent on the second and third rounds of control.
Unlike the number of examined and positive lymph nodes,
which was dependent on more control rounds, errors in the
N classification were less often detected in second (9.6%)
and third rounds (4.8%) The third audit error detection rate
varied from 8.8% (number of positive perirectal lymph
nodes) to 25% (number of examined apical lymph nodes).
DISCUSSION
This study shows that successive rounds of quality
control increased the accuracy and completeness of pathol-
ogy data in a multicenter randomized trial. Major errors,
which involve items related to outcome measures (TNM
stage and circumferential margin involvement), were de-
tected in 3.4% to 17.8% of all cases. These data suggest that
pathology data should be included in a database using the
original pathology reports and controlled by a trained
pathology quality manager.
Although only 32.7% of the CRFs were complete and
correct on examination, the accuracy of our database was high:
Fig 2. Classification migration in the TNM staging resulting from data
completion and correction.
Table 2. Changes in T Classification Resulting From Completion and
Correction (n 5 300)
Controlled Primary
Tumor Classification
Original Primary Tumor Classification




T3 1 2 173 1 2
T4 6 4
Abbreviation: MV, missing value.
Table 3. Changes in N Classification Resulting From Completion and




Original Regional Lymph Node Classification
N0 N1 N2 N3 Nx MV
N0 171 1 2 1
N1 1 55 3
N2 2 40 1 2
N3 5 2 13 1
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3,608 items were correct on the CRF (86.5%). Other validation
studies of databases compared with medical reports show
accuracy of more than 80%. However, some only consider
whether the appropriate organ is indicated (accuracy 99%)7 or
whether the date of birth is correctly entered (accuracy 85%).5
Studies that evaluate more fields of entry reach completeness
levels of 60%4 and correctness levels of 68%.10
Quality control of clinical trials by auditing CRFs and using
the pathology report as the gold standard raises a few ques-
tions. First, what is the relevance of correcting the CRFs if the
quality of data entry is not properly validated? The data entry
process, therefore, was controlled twice; in addition to the
standard control after entry by the data manager, a second
round of control was performed by the pathology quality
manager, which resulted in an accuracy rate of 99.8%, a rate
that is in accordance with other trials.3 Second, how trustwor-
thy is the gold standard? Informational content of the pathol-
ogy report that is insufficient or even incorrect cannot be
corrected by the quality control of the CRFs.
Histopathologic audits in the field of colorectal cancer
reveal that completeness of the entry, for example, of the
circumferential margin as present in the routine pathology
report varies from 8.3% to 78.1%,11 whereas the tumor size
is present in 75.0% to 98.7% of all reports. In a pathology
laboratory in Sheffield, the use of template proformas and
written guidelines did increase the completeness of reports
for circumferential margin involvement from 31% to 100%.
The presence of the TNM stage increased from 0% to
97%.12 However, their study consisted of only 272 routine
reports divided into five auditing rounds and was performed
in one center. Although CRFs are not template proformas,
they provide a guideline for the pathology report, and
therefore, the informational content of our reports may be
considered to be more substantial than most. Furthermore,
the participating pathologists were trained before and during
the trial; they attended lecture sessions and were regularly
provided with newsletters.
Although we did not audit the pathology reports, we can
conclude that a large number of our CRFs were incomplete
(41.3%) as a result of the incompleteness of the reports. The
highest percentage of missing values in the pathology report
was 15% (apical lymph nodes). Although this is good
compared with the literature, we should keep in mind that
data on the CRF are not always present in reports. In studies
for improvement of data collection conducted by the Euro-
pean Organization for Research and Treatment of Cancer,
6% to 30% of data were recorded on the CRFs but were not
retrievable in the hospital records.10,13
Assuming sufficient completeness of the gold standard,
the correctness of the report is the next item of concern. By
using a peer review committee, we tried to ensure a high-
quality pathology database. However, their influence was
Fig 3. Error detection in differ-
ent control rounds. Although most
errors were detected in the first
round, a substantial number of
major errors were detected in ad-
ditional rounds of control.
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restricted because of the limited access to the diagnostic
process. Generally, only one slide was present for reexamina-
tion, though in cases of discrepancy the other slides were
reviewed as well. Pathology peer review and quality control in
other evaluations show a percentage of major or significant
errors that vary from 0.96% to 8.4%.14-18 Significant errors
involve the distinction between malignant and nonmalignant
disorders and lymph node involvement. Most errors involve
mistakes in tumor subclassification.18 Because we did not
obtain our tumor classification from the pathology reports, this
major source of errors may have been eliminated. However, a
certain error rate could not be prevented and should be taken
into account when interpreting clinical trials.
Realizing that the processing of pathology reports may
contribute to their error rate, we analyzed some of the reports
for the possible evidence of typing errors. The cases in which
errors were made in the T and N classifications were reread.
Dutch typing errors in the category of “net” or “niet” (meaning,
respectively, “just” or “not”) in the case of penetration of the
muscularis propria or the serosa may have been crucial in the
T classification, as well as typing errors in the category of
“een” or “geen” (meaning, respectively, “one” or “none”) in
the case of presence of positive lymph nodes. Evaluation of the
use of these words and the context in which they were used
revealed that typing errors were not likely responsible for
errors in the TNM classification and the consequent stage
migration (data not shown).
The high error and missing rates of the circumferential
margin, 18% and 12%, respectively, were disappointing. The
circumferential margin is a key prognostic factor for local
recurrence in rectal carcinoma9 and, therefore, of utmost
importance in our trial. To introduce them to this parameter,
which is relatively new in the Netherlands, pathologists were
provided with training sessions, journal articles, regular news-
letters, and a careful description of the procedure in the trial
protocol. To explain the high error rate in the reporting of the
circumferential margin, we investigated the possible involve-
ment of lymph nodes in the resection margin. According to our
guidelines, the smallest distance from the tumor or positive
lymph nodes or tumor deposition should have been measured.
However, this might have caused confusion and there might
have been cases in which, initially, only the tumor was taken
into account. Of all errors in the circumferential margin, a
small number (7.4%) were caused by only considering the
tumor and not the lymph nodes.
Part of the errors and missing data in the reporting of the
examined and positive lymph nodes may be explained by
the presence of tumor deposits. In the TNM-classification
supplement of 1993,19 it is stated that tumor deposits larger
than 3 mm in diameter should be considered as positive
lymph nodes. In this study, a substantial part of the incorrect
lymph node reporting, 19.4%, was a result of the presence
of tumor deposits. A correction in the number of involved
lymph nodes resulted in N classification migration in three
cases.
Although it has been suggested that the time lapse
between reporting the case and completing the CRF affects
the rate of inconsistency,3 this could not be confirmed in our
study. Nor was it important whether the reporting patholo-
gist or the local TME pathologist filled out the CRF. We
demonstrated a learning effect in the major errors by
comparing the results of pathologists of the PRC with other
pathologists. Apart from their interest in gastrointestinal
pathology, which they might share with local TME pathol-
ogists, they are experienced in the judgement of trial forms,
which may explain their better score. However, a peer
review committee, performing the second quality control
round, is not the ultimate solution for quality assurance of a
multicenter trial. We show that a third round of control is
necessary to guarantee a reliable database.
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Ziekenhuis; B.C. de Vries, Medisch Centrum Haaglanden, locatie Westeinde, Den Haag; P. Heres and J.A. van Oijen, Van Weel-Bethesda Ziekenhuis,
Dirksland; M. van Hillo, Talma Sionsberg, Dokkum; R.J. Oostenbroek, Merwedeziekenhuis, locatie Dordrecht; B. van Ooijen and H. Burger, Drechtsteden
zkh, locatie Refaja, Dordrecht; H.C.J. van der Mijle and R. Looijen, Nij Smellinghe, Drachten; H.J.T. Rutten, Catharina Ziekenhuis; O.J. Repelaer van Driel
and P.H.M. Reemst, Diaconessenhuis, Eindhoven; E.J.Th. Luiten, St Annaziekenhuis, Geldrop; C.M. Dijkhuis, Oosterscheldeziekenhuis, Goes; E.J.
Boerma and R. Silvis, Kennemer Gasthuis, locatie Deo, Haarlem; J.H. Tomee, Stichting Streekziekenhuis Coevorden-Hardenberg, locatie Ro¨pcke Zweers,
Hardenberg; A. Labrie, Spaarne Ziekenhuis, Heemstede; C.G.B.M. Rupert, De Tjongerschans Ziekenhuis, Heerenveen; C.J. van Duin, Atrium Heerlen,
Heerlen; G.J.C.M. Niessen and G. Verspui, Elkerliek Ziekenhuis, locatie Helmond, Helmond; J.W. Juttmann, Ziekenhuis Hilversum, Hilversum; M.W.C.
de Jonge and J.W.D. de Waard, Westfries Gasthuis, Hoorn; D.B.W. de Roy van Zuidewijn and W. Dahmen, Medisch Centrum Leeuwarden, locatie
Medisch Centrum Leeuwarden Zuid, Leeuwarden; K.Welvaart, C.J.H.v.d. Velde, and R.A.E.M. Tollenaar, Leiden University Medical Center; R. Vree and
J.A. Zonnevylle, Diaconessenhuis, Leiden; S.A. da Costa, S.K. Adhin, and P.A. Neijenhuis, Rijnland Ziekenhuis, locatie St Elisabeth, Leiderdorp; F.J.
Idenburg, Medisch Centrum Haaglanden, locatie Antoniushove, Leidschendam; C.E.A.M. Hoynck van Papendrecht, IJsselmeerziekenhuizen, locatie
Zuiderzeeziekenhuis, Lelystad; M.F. von Meyenfeldt, C.G.M.I. Baeten, and G.L. Beets, Academisch Ziekenhuis Maastricht, Maastricht; Th.Wobbes,
Academisch Ziekenhuis Nijmegen St Radboud; E.D.M. Bruggink and L.J.A. Strobbe, Canisius-Wilhelmina Ziekenhuis, Nijmegen; R.A.J. Do¨rr and J.C.H.
van der Waal, Pasteur Ziekenhuis, Oosterhout; C.D. van Duyn, St Anna Ziekenhuis, Oss; J.W.M. Bol and Th.A.A. van den Broek, Waterlandziekenhuis,
Purmerend; J.M.H. Debets and R.J.A. Estourgie, Laurentius Ziekenhuis, Roermond; H.W.P.M. Kemperman, Ziekenhuis Franciscus, Roosendaal; W.R.
Schouten, Academisch Ziekenhuis Rotterdam/Dijkzigt; H.J. Mud, St Clara Ziekenhuis; H.F.Veen, W.F. Weidema, and C.J. van Steensel, Ikazia
Ziekenhuis; J.H. Driebeek-van Dam, Havenziekenhuis; M.A. Paul, Zuiderziekenhuis; Th. Wiggers, Academisch Ziekenhuis Rotterdam/Daniel den Hoed
Kliniek, Rotterdam; J.J. van Bruggen, Schieland Ziekenhuis, Schiedam; E.J. Mulder, Antonius Ziekenhuis, Sneek; A.J. van Beek, Ruwaard van
Puttenziekenhuis, Spijkenisse; H.J.M. Oostvogel, J.A. Roukema, and L.P.H. Leenen, St Elisabeth Ziekenhuis; S.J. Brenninkmeyer and G.P. Gerritsen,
Tweesteden Ziekenhuis, Tilburg; E.B.M. Theunissen, Mesos Medisch Centrum, locatie Overvecht; A. Pronk and P. Leguit, Diakonessenhuis; W.J.C.
Geurts, Mesos Medisch Centrum, locatie Oudenrijn; Th.E. Fick, Centraal Militair Hospitaal; I.H.M. Borel Rinkes and L.W.M. Janssen, Academisch
Ziekenhuis Utrecht, Utrecht; F.A.A.M. Croiset van Uchelen and R.M.H. Roumen, St Joseph Ziekenhuis, Veldhoven; J.F.M. Reinders and C.L.H. van Berlo,
St Maartens Gasthuis, Venlo; C.D.G.W. Verheij and J.J. van der Pol, St Elisabeth Ziekenhuis, Venray; J.H. ten Thije and P. Hintzen, Ziekenhuis Walcheren,
Vlissingen; C.M.G.J.A. Marcoen and I.H. Oei, Diaconessenhuis Voorburg, Voorburg; E.G.M. Leerkotte and J.W.A. van Luijt, Tweesteden Ziekenhuis,
Waalwijk; H.C.M. Verkooyen, St Jans Gasthuis, Weert; J.P. Vente and J. Merkx, Hofpoort Ziekenhuis, Woerden; H. de Morree, Zweedse Rode Kruis
Ziekenhuis, Zierikzee; P.J.J. van Rijn and B. Jas, ’T Lange Land Ziekenhuis, Zoetermeer; and C. Mahabier, Drechtsteden zkh, locatie Jacobus, Zwijndrecht,
the Netherlands.
Participating pathologists: J.P.A Baak, Medisch Centrum Alkmaar, Alkmaar; H. Barrowclough, Lichtenberg, Amersfoort; H.H. Oushoorn, Bovenij
Ziekenhuis; M.F.L. van Velthuysen, Antoni van Leeuwenhoekhuis; W. Spliet, St Lucas Ziekenhuis; G.J.A. Offerhaus, Academisch Medisch Centrum; B.A.
van de Wiel, Andreas Ziekenhuis, Amsterdam; Th.A.J.M. Manschot, Ziekenhuis Centrum Apeldoorn, Apeldoorn; J.W.R. Meyer, Rijnstate Ziekenhuis,
Arnhem; V. Potters, Stichting Pathologische en Cytologisch Laboratorium, Bergen op Zoom; H.V. Stel, Streek Ziekenhuis Gooi Noord, Blaricum; J.H.
Peters and J. Los, St Ignatius Ziekenhuis, Breda; G.W. Verdonk, St Gregorius Ziekenhuis, Brunssum; C. van Krimpen, Stichting Samenwerkende Delftse
Ziekenhuizen, Delft; A.J.M. van Unnik, Groot Ziekengasthuis, Den Bosch; E.C.M. Ooms, Westeinde Ziekenhuis; C.M. Bruijn-van Duinen, Leyenburg;
J.W. Steffelaar, Rode Kruis Ziekenhuis; C.J. Tinga, Bronovo, Den Haag; P.J. Westenend, Pathologisch-anatomisch laboratorium, Dordrecht; I.W.N.
Tan-Go and H.M. Peters, Stichting Pathologische Anatomie en Medische Microbiologie, Eindhoven; J.F. Keuning, Stichting Pathologisch Anatomisch
Laboratorium Kennemerland, Haarlem; K. van Groningen, Spaarne Ziekenhuis Heemstede, Heemstede; P.H.M.H. Theunissen, De Wever-Ziekenhuis,
Heerlen; F.J.J.M. van Merrienboer, Elkerliek Ziekenhuis, Helmond; G. Freling, Stichting Sazinon, Hoogeveen; A.J.K. Grond, Laboratorium voor
Volksgezondheid. Friesland, Leeuwarden; M.C.B. Gorsira, Het Diaconessenhuis Leiden; J.H.J.M. van Krieken, Academisch Ziekenhuis Leiden, Leiden;
J.J. Calame, Rijnland Ziekenhuis, Leiderdorp; E.A. Neefjes-Borst, IJsselmeerziekenhuizen, Lelystad; J.W. Arends, Academisch Ziekenhuis Maastricht,
Maastricht; A.P. Runsink, Streeklaboratorium “Zeeland,” Middelburg; C.A. Seldenrijk, St Antonius Ziekenhuis, Nieuwegein; M.S.M. Pruszczynski,
Academisch Ziekenhuis Nijmegen; M. Mravunac, Canisius-Wilhelmina Ziekenhuis, Nijmegen; W.S. Kwee, St Laurentius Ziekenhuis, Roermond; S.C.
Henzen-Logmans, Daniel den Hoed Kliniek; W.J. Mooi, Academisch Ziekenhuis Dijkzigt; H.F.G.M. van den Ingh, St Clara Ziekenhuis; A. Maes and J.C.
Verhaar, Stichting Pathan; H. Beerman, Zuiderziekenhuis, Rotterdam; A. van der Wurff, Laboratorium Kliniek Pathologie centraal Brabant, Tilburg; M.E.I.
Schipper, Academisch Ziekenhuis Utrecht; H.M. Ruitenberg, Diakonessen Ziekenhuis, Utrecht; R.F.M. Schapers, Stichting Pathologisch Labratorium
Noord Limburg, Venlo; A.P. Willig, St Jans Gasthuis, Weert; and A.G. Balk, Ziekenhuis De Heel, Zaandam.
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